Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03289780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

Study acronym: INSIGHT
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 5000 to confirmed 5006
    • Site details revised at 42 of 42 sites
    v5
  3. Site details revised at 10 of 42 sitesv4
  4. Enrollment target: 1000 to 5000v3 Show 5 more changesShow less
    • Primary completion date: Jun 2019 to Dec 2025
    • Study sites: 28 to 42
    • Study completion date: Dec 2020 to Dec 2025
    • Eligibility criteria shortened, about 54 words
    • Secondary endpoints revised (7)
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to collect information about how a doctor uses the results of the VeriStrat® blood test to guide treatment for non-small cell lung cancer (NSCLC) patients. Understanding how VeriStrat test results influence doctors' decisions and patients' outcomes may help doctors to better treat NSCLC in the future. This study will also look to establish whether new investigational tests can help better predict the effectiveness of certain medications for certain patients. These new investigational tests are only for research purposes at this time.
Trial Details
NCT Number NCT03289780
Lead Sponsor Biodesix, Inc.
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 5,006 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov